文献速递结核与非结核分枝杆菌艾滋病与性传播感染

抗逆转录病毒治疗实现HIV病毒学抑制后结核病风险:丹麦全国前瞻性队列研究

Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

丹麦全国前瞻性队列纳入1995-2017年启动抗逆转录病毒治疗的6849例HIV成人,中位随访7.4年,84例发生结核病,总发病率1.4/1000人年,启动治疗6个月后54例,发病率0.97/1000人年。非丹麦出生、注射吸毒、既往艾滋病定义事件及HIV RNA未抑制者结核风险升高。

要点

  • 启动抗逆转录病毒治疗6个月后结核发病率为0.97/1000人年,风险仍持续存在。
  • 非丹麦出生者调整后发病率比为4.27,注射吸毒者为4.95,既往艾滋病定义事件者为2.05。
  • HIV RNA抑制者结核风险降低,调整后发病率比为0.58。

核心结论

  • 启动抗逆转录病毒治疗6个月后HIV感染者结核风险仍升高,尤其见于移民、注射吸毒者、HIV RNA未抑制者及有结核高流行区暴露或社会健康风险决定因素者。
  • 无上述危险因素的HIV感染者结核风险与普通人群相似,不需要针对性结核筛查策略。

研究设计与样本

  • 丹麦全国前瞻性队列研究,纳入丹麦HIV队列中1995-2017年启动抗逆转录病毒治疗且无既往结核病的全部成年HIV感染者,共6849例,中位随访7.4年。

主要发现

  • 6849例启动抗逆转录病毒治疗的HIV感染者中84例发生结核病,总发病率为1.4/1000人年。
  • 启动治疗6个月后54例发生结核病,发病率为0.97/1000人年(95%CI:1.17-1.79);非丹麦出生者为1.95/1000人年(95%CI:1.34-2.76),无注射吸毒的丹麦出生者为0.36/1000人年(95%CI:0.21-0.62),有注射吸毒的丹麦出生者为2.95/1000人年(95%CI:1.53-5.66)。
  • 病毒血症抑制、无注射吸毒且无已知结核暴露的丹麦出生者风险最低,发病率为0.05/1000人年。
  • 调整分析中,非丹麦出生者调整后发病率比为4.27(95%CI:2.36-7.72),注射吸毒者为4.95(95%CI:2.55-9.62),既往艾滋病定义事件者为2.05(95%CI:1.06-3.94),HIV RNA抑制者的调整后发病率比为0.58(95%CI:0.34-0.99)。
  • 抗逆转录病毒治疗后HIV/结核合并感染者的总死亡率为48.9/1000人年(95%CI:30.4-78.7)。

临床怎么用

  • 作者认为,无上述危险因素的HIV感染者结核风险与普通人群相似,不需要针对性结核筛查策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In countries with low tuberculosis burden, the risk of tuberculosis in people with human immunodeficiency virus (HIV; PWH) once HIV virological suppression is achieved is not fully understood. METHODS: In a nationwide cohort, we included all adult PWH from the Danish HIV Cohort initiating antiretroviral therapy (ART) (1995-2017) without prior tuberculosis disease. We used Kaplan-Meier estimation and Poisson regression to calculate the tuberculosis incidence rate (IR) after 6 months of ART, along with associated risk factors and mortality rates. RESULTS: Among 6849 PWH initiating ART (median follow-up, 7.4 years), 84 developed tuberculosis (IR, 1.4/1000 person-years [PY]), 54 of them >6 months after ART initiation (IR, 0.97/1000 PY [95% confidence interval [CI]: 1.17-1.79); 1.95/1000 PY [1.34-2.76] in non-Danish born, 0.36/1000 PY [.21-.62] in Danish born without injection drug use (IDU), and 2.95/1000 PY [1.53-5.66] in Danish born with IDU). Danish-born individuals with suppressed viremia and no IDU or known tuberculosis exposures had the lowest risk (IR, 0.05/1000 PY). In the adjusted analysis, being non-Danish born (adjusted IR ratio, 4.27 [95% CI: 2.36-7.72]), IDU (4.95 [2.55-9.62]), and previous AIDS-defining events (2.05 [1.06-3.94]) raised the tuberculosis risk, while suppressed HIV RNA levels (0.58 [.34-.99]) reduced it. The overall mortality rate for HIV/tuberculosis coinfected after ART was high, at 48.9/1000 PY (95% CI: 30.4-78.7). CONCLUSIONS: The tuberculosis risk remains elevated in PWH beyond 6 months after ART initiation, especially among migrants, those with IDU, those without suppressed HIV RNA, and those exposed to areas highly endemic for tuberculosis or with social risk determinants of health. Conversely, PWH without these risk factors have a tuberculosis risk similar to the general population and would not require targeted tuberculosis screening strategies.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Virdee AK, Knudtzen FC, Llibre JM, et al. Risk of Tuberculosis After Achieving HIV Virological Suppression on Antiretroviral Therapy: A Danish Nationwide Prospective Cohort Study. Clin Infect Dis. 2025. PMID: 39378332. doi:10.1093/cid/ciae499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。